Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Neoplasm Metastasis 1Melanoma 1Lymphopenia 1HIV Infections 1Glioma 1Carcinoma, Merkel Cell 1AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × efineptakin alfa × Clear all
NCT04594811 2024-08-16

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

NeoImmuneTech

Phase 1 Terminated
10 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡